Mucosal IgA production in response to a killed, Carbigen-adjuvanted vaccine administered intranasally

摘要

For the past several years, alternative routes of vaccine administration have been considered as a possible means to improve the overall immune response. Protective immunity against mucosal pathogens will require novel vaccine strategies to induce mucosal immune responses tailored to anatomic location and to the threat of the invading pathogen.1 The combination of alternative immunization routes and the use of appropriate antigen delivery systems appears to be a rational approach for eliciting protective immunity at mucosal surfaces.2 Human medicine has also recognized that most infections are caused by pathogens which have a mucosal portal of entry, hence the need to develop mucosal vaccines against the myriad of respiratory and enteric infections,especially during early childhood.3 Other reasons for investigating the mucosal route of administration include potential for cross-protection,1 a better point of contact immune response due to heightened levels of mucosal antibody production,5 and theability to circumvent interfering maternal immunity. The results of a field study comparing Emulsigen,M-adjuvanted systemically administered vaccine with the same antigens adjuvanted with Catbigen adjuvant and administered intranasally were presented atAASV in 2016.4 No statistical differences were found between the production parameters measured and IgG and IgA levels in serum. The goal of this study was to evaluate the level of mucosal IgA produced by a killed, Carbigen-adjuvanted IAV-S vaccine compared to placebo control.